GYRE
GYRE THERAPEUTICS, INC.
$5.93
-2.15%
$575.4M
No data for this timeframe.
Vol
Market Cap$575.4M
Cap SizeSmall Cap
Inst. Holders27 funds
Inst. Value$18.0M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 12S
Insider Net $-$821.2K
SEC Reports4
Press Releases2
Recent Activity
Jun 10, 2026
Insider
Ye Weiguo acquired via exercise 6,418 shares
Chief Operating Officer @ $0.7500 ($4.8K)
Jun 10, 2026
Insider
Ye Weiguo sold 6,418 shares
Chief Operating Officer @ $6.21 ($39.9K)
Jun 9, 2026
Insider
Ye Weiguo acquired via exercise 14,500 shares
Chief Operating Officer @ $0.7500 ($10.9K)
Jun 2, 2026
SEC
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the co
8-K — Impact 4/10
May 14, 2026
SEC
Gyre Therapeutics filed an 8-K furnishing an investor presentation under Item 7.01, to be presented at a scientific conf
8-K — Impact 5/10
May 8, 2026
earnings_calendar
GYRE Q1 2026 Earnings Scheduled — 2026-05-08
May 4, 2026
SEC
Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. on May 4, 2026, in a transaction valued at approximat
8-K, DEFA14A — Impact 7/10
Inst.
DIMENSIONAL FUND ADVISORS LP — DOUBLED
25,268 shares ($176.1K)
Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$18.67 (Oct 2025)
Current $5.93
Low $18.00
Median $18.00
High $20.00
3 analysts
$18.00
$20.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 10, 2025 | Jefferies | INITIATE | Buy |
| Aug 26, 2025 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 | $-0.09 — $0.00 | 0% YoY | 3 |
| Next Q | $-0.07 | $-0.13 — $-0.02 | -344% YoY | 3 |
| Current FY | $-0.29 | $-0.45 — $-0.12 | -1550% YoY | 3 |
| Next FY | $-0.12 | $-0.23 — $0.00 | 60% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the co
Jun 2, 2026
NEUTRAL
8-K
5/10
Gyre Therapeutics filed an 8-K furnishing an investor presentation under Item 7.01, to be presented at a scientific conf
May 14, 2026
BULLISH
Press
7/10
Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. for approximately $300 million, gaining a commercial-
May 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $6.9M | — |
| BlackRock, Inc. | $5.3M | — |
| STATE STREET CORP | $1.5M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.2M | ADD |
| VANGUARD FIDUCIARY TRUST CO | $959.6K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Ye Weiguo | M | $4.8K |
| Jun 10, 2026 | Ye Weiguo | SELL | $39.9K |
| Jun 9, 2026 | Ye Weiguo | M | $10.9K |
| Jun 9, 2026 | Ye Weiguo | SELL | $89.0K |
| Jun 8, 2026 | Luo Ying | A | $0.00 |
27 institutional holders with $18.0M total value (2,580,373 shares) as of 2026-Q1. Top holders: VANGUARD, BlackRock,, STATE. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 984,204 | $6.9M | 38.1% | — |
| 2 | BlackRock, Inc. | 758,630 | $5.3M | 29.4% | — |
| 3 | STATE STREET CORP | 216,326 | $1.5M | 8.4% | ADD +38.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 165,238 | $1.2M | 6.4% | ADD +37.1% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 137,682 | $959.6K | 5.3% | — |
| 6 | GOLDMAN SACHS GROUP INC | 73,122 | $509.7K | 2.8% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 69,814 | $486.6K | 2.7% | — |
| 8 | DIMENSIONAL FUND ADVISORS LP | 25,268 | $176.1K | 1.0% | DOUBLED +131.8% |
| 9 | ALLIANCEBERNSTEIN L.P. | 21,830 | $154.1K | 0.9% | — |
| 10 | STRS OHIO | 21,100 | $147.1K | 0.8% | ADD +58.6% |
| 11 | FMR LLC | 18,717 | $130.5K | 0.7% | ADD +81.6% |
| 12 | Brevan Howard Capital Management LP | 13,808 | $96.2K | 0.5% | — |
| 13 | RHUMBLINE ADVISERS | 13,116 | $91.4K | 0.5% | ADD +45.3% |
| 14 | DEUTSCHE BANK AG\ | 10,613 | $74.0K | 0.4% | — |
| 15 | BANK OF AMERICA CORP /DE/ | 10,538 | $73.5K | 0.4% | ADD +45.9% |
| 16 | Vanguard Global Advisers, LLC | 9,983 | $69.6K | 0.4% | — |
| 17 | MORGAN STANLEY | 8,641 | $60.2K | 0.3% | NEAR_EXIT -84.1% |
| 18 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 5,617 | $39.1K | 0.2% | ADD +30.4% |
| 19 | ROYAL BANK OF CANADA | 5,605 | $39.0K | 0.2% | DOUBLED +1497.4% |
| 20 | WELLS FARGO & COMPANY/MN | 4,290 | $29.9K | 0.2% | DOUBLED +132.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 10,903 | 25,268 | +131.8% | $176.1K | 2026-Q1 |
| FMR LLC | ADD | 10,304 | 18,717 | +81.6% | $130.5K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 54,498 | 8,641 | -84.1% | $60.2K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 2,003 | 1,124 | -43.9% | $7.8K | 2026-Q1 |
| CWM, LLC | DOUBLED | 36 | 104 | +188.9% | $725.00 | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 123,386 | 169,158 | +37.1% | $1.2M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 8,981 | 54,498 | +506.8% | $384.8K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 39,000 | 24,800 | -36.4% | $175.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 5,558 | 12,919 | +132.4% | $91.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 6,687 | 9,759 | +45.9% | $68.9K | 2025-Q4 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 4,203 | 5,481 | +30.4% | $38.7K | 2025-Q4 |
| Russell Investments Group, Ltd. | ADD | 1,124 | 2,003 | +78.2% | $14.1K | 2025-Q4 |
| Legal & General Group Plc | ADD | 860 | 1,405 | +63.4% | $9.9K | 2025-Q4 |
| CWM, LLC | TRIM | 123 | 43 | -65.0% | — | 2025-Q3 |
| UBS Group AG | DOUBLED | 8,639 | 22,962 | +165.8% | $171.3K | 2025-Q3 |
| STRS OHIO | ADD | 13,300 | 21,100 | +58.6% | $157.4K | 2025-Q3 |
| BARCLAYS PLC | TRIM | 24,004 | 13,396 | -44.2% | $99.9K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 35,258 | 8,981 | -74.5% | $67.0K | 2025-Q3 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 7,413 | 4,203 | -43.3% | $31.4K | 2025-Q3 |
| Legal & General Group Plc | TRIM | 1,513 | 860 | -43.2% | $6.4K | 2025-Q3 |
| NISA INVESTMENT ADVISORS, LLC | ADD | 59 | 102 | +72.9% | $761.00 | 2025-Q3 |
| STATE STREET CORP | ADD | 128,773 | 177,768 | +38.0% | $1.3M | 2025-Q2 |
| RHUMBLINE ADVISERS | ADD | 11,141 | 16,186 | +45.3% | $119.0K | 2025-Q2 |
| UBS Group AG | TRIM | 24,306 | 8,639 | -64.5% | $63.5K | 2025-Q2 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 4,169 | 7,413 | +77.8% | $54.5K | 2025-Q2 |
6 unique insiders with 27 transactions. Net insider value: -$821.2K ($0.00 bought, $821.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 6,418 | $0.7500 | $4.8K |
| Jun 10, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 6,418 | $6.21 | $39.9K |
| Jun 9, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 14,500 | $0.7500 | $10.9K |
| Jun 9, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 14,500 | $6.14 | $89.0K |
| Jun 8, 2026 | Luo Ying | Chief Executive Officer | AWARD | 120,000 | — | — |
| Jun 8, 2026 | Bergmann Joshua Benjamin | GC and Corporate Secretary | AWARD | 50,000 | — | — |
| Jun 5, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 15,401 | $0.7500 | $11.6K |
| Jun 5, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 15,401 | $6.40 | $98.6K |
| Jun 4, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 19,575 | $6.13 | $120.0K |
| Jun 4, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 19,575 | $0.7500 | $14.7K |
| May 21, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 12,820 | $0.7500 | $9.6K |
| May 21, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 12,820 | $6.15 | $78.8K |
| May 20, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 9,400 | $0.7500 | $7.0K |
| May 20, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 9,400 | $6.15 | $57.8K |
| May 19, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 9,120 | $0.7500 | $6.8K |
| May 19, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 9,120 | $6.37 | $58.1K |
| May 18, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 200 | $0.7500 | $150.00 |
| May 18, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 200 | $6.62 | $1.3K |
| May 15, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 13,100 | $0.7500 | $9.8K |
| May 15, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 13,100 | $6.65 | $87.1K |
| May 14, 2026 | Ye Weiguo | Chief Operating Officer | SELL | 15,580 | $6.91 | $107.7K |
| May 14, 2026 | Ye Weiguo | Chief Operating Officer | EXERCISE | 15,580 | $0.7500 | $11.7K |
| May 14, 2026 | Zhang Ping | Director | D | 250,000 | — | — |
| May 6, 2026 | Luo Ying | Chief Executive Officer | SELL | 10,136 | $8.04 | $81.5K |
| May 5, 2026 | Luo Ying | Chief Executive Officer | SELL | 179 | $8.01 | $1.4K |
| May 4, 2026 | Eastling Thomas Wilson | Chief Financial Officer | AWARD | 95,060 | — | — |
| May 4, 2026 | GNI Group Ltd. | 10%+ Owner | J | 458,120 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
4/10
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentati
Jun 2, 2026
NEUTRAL
8-K
5/10
Gyre Therapeutics filed an 8-K furnishing an investor presentation under Item 7.01, to be presented
May 14, 2026
BULLISH
8-K, DEFA14A
7/10
Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. on May 4, 2026, in a transaction
May 4, 2026
NEUTRAL
8-K
5/10
Gyre Therapeutics provided forward-looking guidance at an investor conference, highlighting potentia
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Oct 2025): 89% buy across 9 analysts — 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$18.67 mean target (Oct 2025)
$18.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $5.93 |
| Target Low | $18.00 |
| Target Mean | $18.67 |
| Target Median | $18.00 |
| Target High | $20.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.09 | $0.00 | 0.0% | — | 0↑ 1↓ | $0.0B | -1.1% | 3 |
| Next Q 2026-09-30 |
$-0.07 | $-0.13 | $-0.02 | -344.4% | — | 0↑ 2↓ | $0.0B | -13.4% | 3 |
| Current FY 2026-12-31 |
$-0.29 | $-0.45 | $-0.12 | -1550.0% | — | 0↑ 3↓ | $0.1B | -12.3% | 3 |
| Next FY 2027-12-31 |
$-0.12 | $-0.23 | $0.00 | 60.3% | — | 0↑ 2↓ | $0.1B | 27.8% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.057 | |
| 7d ago | $0.000 | -0.057 |
| 30d ago | $0.000 | -0.057 |
| 60d ago | $0.050 | -0.107 |
| 90d ago | $0.050 | -0.107 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 10, 2025 | Jefferies | INITIATE | — | Buy |
| Aug 26, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 8, 2026
earnings_calendar
GYRE Q1 2026 Earnings Scheduled — 2026-05-08
May 7, 2026
earnings
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 4, 2026
m_and_a
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Mar 12, 2026
earnings
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update